1
|
Zhu W, Wei M, Wang Y, Wang G, Wang J, Rao H. Oxidative Nickel-Catalyzed ortho-C-H Amination of (Iso)quinolines with Alicyclic Amines Directed by a Sacrificial N-Oxide Group. Org Lett 2024; 26:912-916. [PMID: 38270506 DOI: 10.1021/acs.orglett.3c04193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2024]
Abstract
Transition metal (TM)-catalyzed direct amination of C-H bonds on free or fused pyridine (Py) rings with free amines still remains scarce because amines and the Py ring tend to adopt a nonproductive N-bound coordination with many TMs, leading to a significant decrease of catalytic reactivity. We herein disclose a nickel-catalyzed and a sacrificial N-oxide group directed oxidative coupling of (iso)quinolyl C-H bonds and alicyclic amines, which furnishes bioimportant amino(iso)quinolines efficiently and selectively in a single step. Noteworthy, this protocol avoids the use of aggressive reactants and very strong bases usually required when aminating on nonoxidized Py rings.
Collapse
Affiliation(s)
- Weiqi Zhu
- Department of Chemistry, Capital Normal University, Beijing 100048, P. R. China
| | - Min Wei
- Department of Chemistry, Capital Normal University, Beijing 100048, P. R. China
| | - Yanrui Wang
- Department of Chemistry, Capital Normal University, Beijing 100048, P. R. China
| | - Guo Wang
- Department of Chemistry, Capital Normal University, Beijing 100048, P. R. China
| | - Jianchun Wang
- Department of Chemistry, Capital Normal University, Beijing 100048, P. R. China
| | - Honghua Rao
- Department of Chemistry, Capital Normal University, Beijing 100048, P. R. China
- Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing 100084, P. R. China
| |
Collapse
|
2
|
Mekheimer RA, Al-Sheikh MA, Medrasi HY, Sadek KU. Advancements in the synthesis of fused tetracyclic quinoline derivatives. RSC Adv 2020; 10:19867-19935. [PMID: 35520416 PMCID: PMC9054245 DOI: 10.1039/d0ra02786c] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Accepted: 05/07/2020] [Indexed: 11/21/2022] Open
Abstract
Fused tetracyclic systems containing a quinoline nucleus represent an important class of heterocyclic bioactive natural products and pharmaceuticals because of their significant and wide-spectrum biological properties. Several of these compounds have been obtained with diverse pharmacological and biological activities, such as antiplasmodial, antifungal, antibacterial, potent antiparasitic, antiproliferative, anti-tumor and anti-inflammatory activities. This information will be beneficial for medicinal chemists in the field of drug discovery to design and synthesize new fused tetracyclic quinolines as potent therapeutical agents. This review article provides a comprehensive report regarding the methods developed for the synthesis of fused tetracyclic quinolines reported so far (till October 2019). The article includes synthesis by one-pot domino reaction, microwave synthesis using a catalyst, using ionic liquids, photocatalytic synthesis (UV radiation), Pfitzinger reaction, I2-catalyzed cyclization reaction, Wittig reaction, cascade reaction, imino Diels-Alder reaction, Friedel-Crafts reaction, CDC reaction, solvent-free reactions and using small chiral organic molecules as catalysts. To the best of our knowledge, this is the first review focused on the synthesis of fused tetracyclic quinolines along with mechanistic aspects.
Collapse
Affiliation(s)
- Ramadan A Mekheimer
- Department of Chemistry, Faculty of Science, Minia University Minia 61519 Egypt
| | - Mariam A Al-Sheikh
- Department of Chemistry, Faculty of Science, University of Jeddah Jeddah 21589 Saudi Arabia
| | - Hanadi Y Medrasi
- Department of Chemistry, Faculty of Science, University of Jeddah Jeddah 21589 Saudi Arabia
| | - Kamal U Sadek
- Department of Chemistry, Faculty of Science, Minia University Minia 61519 Egypt
| |
Collapse
|
3
|
Helal MA, Chittiboyina AG, Avery MA. Identification of a new small molecule chemotype of Melanin Concentrating Hormone Receptor-1 antagonists using pharmacophore-based virtual screening. Bioorg Med Chem Lett 2019; 29:126741. [PMID: 31678007 DOI: 10.1016/j.bmcl.2019.126741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Revised: 10/01/2019] [Accepted: 10/03/2019] [Indexed: 10/25/2022]
Abstract
MCH receptor is a G protein-coupled receptor with two subtypes R1 and R2. Many studies have demonstrated the role of MCH-R1 in feeding and energy homeostasis. It has been proven that oral administration of small molecule MCH-R1 antagonists significantly reduces food intake and causes a dose-dependent weight loss. In this study, two ligand-based pharmacophores were developed and validated based on recently published MCH-R1 antagonists with diverse structures. Successful pharmacophores had one hydrogen bond acceptor, one positive ionizable, one ring aromatic and two or three hydrophobic groups. These 3D-QSAR models were used for virtual screening of the ZINC chemical database resulting in the identification of nine compounds with more than 50% displacement of radiolabeled MCH at a 20 μM concentration. Moreover, four of these compounds showed antagonistic activities in Aequorin functional assay, including MH-3 which is the first MCH-R1 antagonist based on a diazaspiro[4.5]decane scaffold. The most active compounds were also docked into our previously published MCH-R1 homology model to gain insights into their binding determinants. These compounds could represent a viable starting scaffold for the design of potent MCH-R1 antagonists with improved pharmacokinetic properties as an effective treatment for obesity.
Collapse
Affiliation(s)
- Mohamed A Helal
- University of Science and Technology, Biomedical Sciences Program, Zewail City of Science and Technology, October Gardens, 6th of October, Giza 12578, Egypt; Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.
| | - Amar G Chittiboyina
- National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS 38677, United States
| | - Mitchell A Avery
- Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, United States
| |
Collapse
|
4
|
Mekheimer RA, Al-Sheikh MA, Medrasi HY, Bahatheg GA, Sadek KU. Chloroquinoline-3-carbonitriles: Synthesis and Reactions. CURR ORG CHEM 2019. [DOI: 10.2174/1385272823666190516120946] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We herein describe the first review which aims to focus soberly the various
synthetic methods and chemical reactions of chloroquinoline-3-carbonitrile derivatives.
The reactions are subdivided into groups that cover reactions of chloro substituent at 2 or
4 and 2,4 positions, as well as cyano substituent at 3 position and reactions which involve
both groups. Most types of reactions have been successfully applied and used in the production
of biologically active compounds.
Collapse
Affiliation(s)
- Ramadan A. Mekheimer
- Department of Chemistry, Faculty of Science, Minia University, Minia 61519, Egypt
| | - Mariam A. Al-Sheikh
- Department of Chemistry, Faculty of Science, University of Jeddah, P.O. Box 80327, Jeddah 21589, Saudi Arabia
| | - Hanadi Y. Medrasi
- Department of Chemistry, Faculty of Science, University of Jeddah, P.O. Box 80327, Jeddah 21589, Saudi Arabia
| | - Ghayah A. Bahatheg
- Department of Chemistry, Faculty of Science, University of Jeddah, P.O. Box 80327, Jeddah 21589, Saudi Arabia
| | - Kamal U. Sadek
- Department of Chemistry, Faculty of Science, Minia University, Minia 61519, Egypt
| |
Collapse
|
5
|
Gold‐Catalyzed Intermolecular [4+2] Annulation of 2‐Ethynylanilines with Ynamides: An Access to Substituted 2‐Aminoquinolines. Adv Synth Catal 2018. [DOI: 10.1002/adsc.201800341] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
6
|
Irwin JJ, Gaskins G, Sterling T, Mysinger MM, Keiser MJ. Predicted Biological Activity of Purchasable Chemical Space. J Chem Inf Model 2017; 58:148-164. [PMID: 29193970 PMCID: PMC5780839 DOI: 10.1021/acs.jcim.7b00316] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
![]()
Whereas
400 million distinct compounds are now purchasable within
the span of a few weeks, the biological activities of most are unknown.
To facilitate access to new chemistry for biology, we have combined
the Similarity Ensemble Approach (SEA) with the maximum Tanimoto similarity
to the nearest bioactive to predict activity for every commercially
available molecule in ZINC. This method, which we label SEA+TC, outperforms
both SEA and a naïve-Bayesian classifier via predictive performance
on a 5-fold cross-validation of ChEMBL’s bioactivity data set
(version 21). Using this method, predictions for over 40% of compounds
(>160 million) have either high significance (pSEA ≥ 40),
high
similarity (ECFP4MaxTc ≥ 0.4), or both, for one or more of
1382 targets well described by ligands in the literature. Using a
further 1347 less-well-described targets, we predict activities for
an additional 11 million compounds. To gauge whether these predictions
are sensible, we investigate 75 predictions for 50 drugs lacking a
binding affinity annotation in ChEMBL. The 535 million predictions
for over 171 million compounds at 2629 targets are linked to purchasing
information and evidence to support each prediction and are freely
available via https://zinc15.docking.org and https://files.docking.org.
Collapse
Affiliation(s)
- John J Irwin
- Department of Pharmaceutical Chemistry, University of California, San Francisco , Byers Hall, 1700 4th Street, San Francisco, California 94158-2330, United States
| | - Garrett Gaskins
- Department of Pharmaceutical Chemistry, University of California, San Francisco , Byers Hall, 1700 4th Street, San Francisco, California 94158-2330, United States.,Institute for Neurodegenerative Diseases, University of California, San Francisco , 675 Nelson Rising Lane, San Francisco, California 94158, United States.,Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco , Byers Hall, 1700 4th Street, San Francisco, California 94158, United States.,Institute for Computational Health Sciences, University of California, San Francisco , 550 16th Street, San Francisco, California 94158, United States
| | - Teague Sterling
- Department of Pharmaceutical Chemistry, University of California, San Francisco , Byers Hall, 1700 4th Street, San Francisco, California 94158-2330, United States
| | - Michael M Mysinger
- Department of Pharmaceutical Chemistry, University of California, San Francisco , Byers Hall, 1700 4th Street, San Francisco, California 94158-2330, United States
| | - Michael J Keiser
- Department of Pharmaceutical Chemistry, University of California, San Francisco , Byers Hall, 1700 4th Street, San Francisco, California 94158-2330, United States.,Institute for Neurodegenerative Diseases, University of California, San Francisco , 675 Nelson Rising Lane, San Francisco, California 94158, United States.,Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco , Byers Hall, 1700 4th Street, San Francisco, California 94158, United States.,Institute for Computational Health Sciences, University of California, San Francisco , 550 16th Street, San Francisco, California 94158, United States
| |
Collapse
|
7
|
Schaller D, Hagenow S, Alpert G, Naß A, Schulz R, Bermudez M, Stark H, Wolber G. Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands. ACS Med Chem Lett 2017. [PMID: 28626527 DOI: 10.1021/acsmedchemlett.7b00118] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
In this study, we report a ligand-centric data mining approach that guided the identification of suitable target profiles for treating obesity. The newly developed method is based on identifying target pairs for synergistic positive effects and also encompasses the exclusion of compounds showing a detrimental effect on obesity treatment (off-targets). Ligands with known activity against obesity-relevant targets were compared using fingerprint representations. Similar compounds with activities to different targets were evaluated for the mechanism of action since activation or deactivation of drug targets determines the pharmacological effect. In vitro validation of the modeling results revealed that three known modulators of melanin-concentrating hormone receptor 1 (MCHR1) show a previously unknown submicromolar affinity to the histamine H3 receptor (H3R). This synergistic activity may present a novel therapeutic option against obesity.
Collapse
Affiliation(s)
- David Schaller
- Pharmaceutical
and Medicinal Chemistry, Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany
| | - Stefanie Hagenow
- Pharmaceutical
and Medicinal Chemistry, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany
| | - Gina Alpert
- Pharmaceutical
and Medicinal Chemistry, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany
| | - Alexandra Naß
- Pharmaceutical
and Medicinal Chemistry, Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany
| | - Robert Schulz
- Pharmaceutical
and Medicinal Chemistry, Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany
| | - Marcel Bermudez
- Pharmaceutical
and Medicinal Chemistry, Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany
| | - Holger Stark
- Pharmaceutical
and Medicinal Chemistry, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany
| | - Gerhard Wolber
- Pharmaceutical
and Medicinal Chemistry, Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany
| |
Collapse
|
8
|
Johansson A, Löfberg C, Antonsson M, von Unge S, Hayes MA, Judkins R, Ploj K, Benthem L, Lindén D, Brodin P, Wennerberg M, Fredenwall M, Li L, Persson J, Bergman R, Pettersen A, Gennemark P, Hogner A. Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties. J Med Chem 2016; 59:2497-511. [PMID: 26741166 DOI: 10.1021/acs.jmedchem.5b01654] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
A novel series of melanin concentrating hormone receptor 1 (MCHr1) antagonists were the starting point for a drug discovery program that culminated in the discovery of 103 (AZD1979). The lead optimization program was conducted with a focus on reducing lipophilicity and understanding the physicochemical properties governing CNS exposure and undesired off-target pharmacology such as hERG interactions. An integrated approach was taken where the key assay was ex vivo receptor occupancy in mice. The candidate compound 103 displayed appropriate lipophilicity for a CNS indication and showed excellent permeability with no efflux. Preclinical GLP toxicology and safety pharmacology studies were without major findings and 103 was taken into clinical trials.
Collapse
Affiliation(s)
- Anders Johansson
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Christian Löfberg
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Madeleine Antonsson
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Sverker von Unge
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Martin A Hayes
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Robert Judkins
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Karolina Ploj
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Lambertus Benthem
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Daniel Lindén
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Peter Brodin
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Marie Wennerberg
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Marléne Fredenwall
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Lanna Li
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Joachim Persson
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Rolf Bergman
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Anna Pettersen
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Peter Gennemark
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Anders Hogner
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| |
Collapse
|
9
|
Sharma P, Liu RS. Cu-Catalyzed Aerobic Oxidative Cyclizations of 3-N-Hydroxyamino-1,2-propadienes with Alcohols, Thiols, and Amines To Form α-O-,S-, andN-Substituted 4-Methylquinoline Derivatives. Chemistry 2015; 21:4590-4. [DOI: 10.1002/chem.201406317] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Indexed: 12/11/2022]
|
10
|
Kumar SV, Muthusubramanian S, Perumal S. Facile “on water” domino reactions for the expedient synthesis of 2H-thiopyrano[2,3-b]quinolines. RSC Adv 2015. [DOI: 10.1039/c5ra04795a] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
A facile synthesis of novel 3-nitro-2-aryl-2H-thiopyrano[2,3-b]quinolines from the domino reactions of 2-mercaptoquinoline-3-carbaldehyde and substituted β-nitrostyrenes in the presence of triethylamine (TEA) in water is described.
Collapse
Affiliation(s)
- Sundaravel Vivek Kumar
- Department of Organic Chemistry
- School of Chemistry
- Madurai Kamaraj University
- Madurai – 625 021
- India
| | | | - Subbu Perumal
- Department of Organic Chemistry
- School of Chemistry
- Madurai Kamaraj University
- Madurai – 625 021
- India
| |
Collapse
|
11
|
Washburn WN, Manfredi M, Devasthale P, Zhao G, Ahmad S, Hernandez A, Robl JA, Wang W, Mignone J, Wang Z, Ngu K, Pelleymounter MA, Longhi D, Zhao R, Wang B, Huang N, Flynn N, Azzara AV, Barrish JC, Rohrbach K, Devenny JJ, Rooney S, Thomas M, Glick S, Godonis HE, Harvey SJ, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Maxwell BD, Yang H, Apedo A, Gemzik B, Janovitz EB, Huang C, Zhang L, Freeden C, Murphy BJ. Identification of a Nonbasic Melanin Hormone Receptor 1 Antagonist as an Antiobesity Clinical Candidate. J Med Chem 2014; 57:7509-22. [DOI: 10.1021/jm500026w] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- William N. Washburn
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Mark Manfredi
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Pratik Devasthale
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Guohua Zhao
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Saleem Ahmad
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Andres Hernandez
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Jeffrey A. Robl
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Wei Wang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - James Mignone
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Zhenghua Wang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Khehyong Ngu
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Mary Ann Pelleymounter
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Daniel Longhi
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Rulin Zhao
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Bei Wang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Ning Huang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Neil Flynn
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Anthony V. Azzara
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Joel C. Barrish
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Kenneth Rohrbach
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - James J. Devenny
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Suzanne Rooney
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Michael Thomas
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Susan Glick
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Helen E. Godonis
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Susan J. Harvey
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Mary Jane Cullen
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Hongwei Zhang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Christian Caporuscio
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Paul Stetsko
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Mary Grubb
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Brad D. Maxwell
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Hong Yang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Atsu Apedo
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Brian Gemzik
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Evan B. Janovitz
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Christine Huang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Lisa Zhang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Chris Freeden
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Brian J. Murphy
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| |
Collapse
|
12
|
Wu M, Li Y, Fu X, Wang J, Zhang S, Yang L. Profiling the interaction mechanism of quinoline/quinazoline derivatives as MCHR1 antagonists: an in silico method. Int J Mol Sci 2014; 15:15475-502. [PMID: 25257526 PMCID: PMC4200842 DOI: 10.3390/ijms150915475] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2014] [Revised: 06/30/2014] [Accepted: 08/19/2014] [Indexed: 12/13/2022] Open
Abstract
Melanin concentrating hormone receptor 1 (MCHR1), a crucial regulator of energy homeostasis involved in the control of feeding and energy metabolism, is a promising target for treatment of obesity. In the present work, the up-to-date largest set of 181 quinoline/quinazoline derivatives as MCHR1 antagonists was subjected to both ligand- and receptor-based three-dimensional quantitative structure–activity (3D-QSAR) analysis applying comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). The optimal predictable CoMSIA model exhibited significant validity with the cross-validated correlation coefficient (Q2) = 0.509, non-cross-validated correlation coefficient (R2ncv) = 0.841 and the predicted correlation coefficient (R2pred) = 0.745. In addition, docking studies and molecular dynamics (MD) simulations were carried out for further elucidation of the binding modes of MCHR1 antagonists. MD simulations in both water and lipid bilayer systems were performed. We hope that the obtained models and information may help to provide an insight into the interaction mechanism of MCHR1 antagonists and facilitate the design and optimization of novel antagonists as anti-obesity agents.
Collapse
Affiliation(s)
- Mingwei Wu
- Key Laboratory of Industrial Ecology and Environmental Engineering (MOE), Dalian University of Technology, Dalian 116024, China.
| | - Yan Li
- Key Laboratory of Industrial Ecology and Environmental Engineering (MOE), Dalian University of Technology, Dalian 116024, China.
| | - Xinmei Fu
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China.
| | - Jinghui Wang
- Key Laboratory of Industrial Ecology and Environmental Engineering (MOE), Dalian University of Technology, Dalian 116024, China.
| | - Shuwei Zhang
- Key Laboratory of Industrial Ecology and Environmental Engineering (MOE), Dalian University of Technology, Dalian 116024, China.
| | - Ling Yang
- Laboratory of Pharmaceutical Resource Discovery, Dalian Institute of Chemical Physics, Graduate School of the Chinese Academy of Sciences, Dalian 116023, China.
| |
Collapse
|
13
|
Wu L, Wang Y, Song H, Tang L, Zhou Z, Tang C. Synthesis of Optically Active 2H-Thiopyrano[2,3-b]quinolines with Three Contiguous Stereocentersviaan Organocatalytic Asymmetric Tandem Michael-Henry Reaction. Adv Synth Catal 2013. [DOI: 10.1002/adsc.201300086] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
14
|
Generation of three-dimensional pharmacophore models. WILEY INTERDISCIPLINARY REVIEWS: COMPUTATIONAL MOLECULAR SCIENCE 2012. [DOI: 10.1002/wcms.1129] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
15
|
Bingham M, Rankovic Z. Medicinal Chemistry Challenges in CNS Drug Discovery. DRUG DISCOVERY FOR PSYCHIATRIC DISORDERS 2012. [DOI: 10.1039/9781849734943-00465] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to avoid injury from external insults and toxins. Penetrating the blood-brain barrier (BBB) to achieve the drug concentrations required for efficacious target receptor occupancy in the brain region of interest is a unique and significant challenge facing medicinal chemists working on CNS targets. Prospective design of molecules with optimal brain exposure and safety profile requires in-depth understanding of the fundamental relationships between physicochemical properties and in vitro and in vivo outcomes. Following from the now widely accepted “rule of five” guidelines for the design of oral drugs, the physicochemical properties for brain penetration have been extensively studied in an effort to define the characteristics of successful CNS drug candidates. Several key physicochemical properties have been identified that influence the rate of brain permeability and extent of brain penetration, including H-bonding potential, molecular weight, lipophilicity, polar surface area (PSA), ionization state and rotatable bond count. The ability to process this information effectively and engage in multi-parameter prospective design ultimately determines the success in delivering high-quality drug candidates that are suitable robustly to test hypotheses in the clinic and have good probability of reaching the market. This chapter focuses on the medicinal chemistry aspects of drug candidate optimization particular to the CNS therapeutic area, such as crossing the blood-brain barrier (BBB), as well as safety-related issues frequently challenging CNS programs such as hERG selectivity and phospholipidosis.
Collapse
Affiliation(s)
| | - Zoran Rankovic
- Eli Lilly and Company893 South Delaware Street, Indianapolis, IN
| |
Collapse
|
16
|
Delattin N, Bardiot D, Marchand A, Chaltin P, De Brucker K, Cammue BPA, Thevissen K. Identification of fungicidal 2,6-disubstituted quinolines with activity against Candida biofilms. Molecules 2012; 17:12243-51. [PMID: 23079495 PMCID: PMC6268363 DOI: 10.3390/molecules171012243] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2012] [Revised: 09/27/2012] [Accepted: 10/15/2012] [Indexed: 11/16/2022] Open
Abstract
We have identified two subseries of 2,6-disubstituted quinolines, consisting of 6-amide and 6-urea derivatives, which are characterized by fungicidal activity against Candida albicans with minimal fungicidal concentration (MFC) values < 15 µM. The 6-amide derivatives displayed the highest fungicidal activity against C. albicans, in particular compounds 1, 5 and 6 characterized by MFC values of 6.25–12.5 µM. Compounds 1 and 5 of this series displayed fungicidal activity against the emerging pathogen Candida glabrata(MFC < 50 µM). The 6-amide derivatives 1, 2, 5, and 6 and the 6-urea derivatives 10, 12, 13 and 15 could also eradicate C. albicans biofilms. We found that the 6-urea derivatives 10, 13, and 15 induced accumulation of endogenous reactive oxygen species in Candida albicans biofilms.
Collapse
Affiliation(s)
- Nicolas Delattin
- Centre of Microbial and Plant Genetics, Katholieke Universiteit Leuven, Kasteelpark Arenberg 20, B-3001, Heverlee, Belgium
| | - Dorothée Bardiot
- CISTIM Leuven vzw, Minderbroedersstraat 12, B-3000, Leuven, Belgium
| | - Arnaud Marchand
- CISTIM Leuven vzw, Minderbroedersstraat 12, B-3000, Leuven, Belgium
| | - Patrick Chaltin
- CISTIM Leuven vzw, Minderbroedersstraat 12, B-3000, Leuven, Belgium
- Centre for Drug Design and Discovery, Minderbroedersstraat 8a, B-3000, Leuven, Belgium
| | - Katrijn De Brucker
- Centre of Microbial and Plant Genetics, Katholieke Universiteit Leuven, Kasteelpark Arenberg 20, B-3001, Heverlee, Belgium
| | - Bruno P. A. Cammue
- Centre of Microbial and Plant Genetics, Katholieke Universiteit Leuven, Kasteelpark Arenberg 20, B-3001, Heverlee, Belgium
- Author to whom correspondence should be addressed; ; Tel.: +32-16-329-682; Fax: +32-16-321-966
| | - Karin Thevissen
- Centre of Microbial and Plant Genetics, Katholieke Universiteit Leuven, Kasteelpark Arenberg 20, B-3001, Heverlee, Belgium
| |
Collapse
|
17
|
Högberg T, Frimurer TM, Sasmal PK. Melanin concentrating hormone receptor 1 (MCHR1) antagonists—Still a viable approach for obesity treatment? Bioorg Med Chem Lett 2012; 22:6039-47. [DOI: 10.1016/j.bmcl.2012.08.025] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2012] [Revised: 07/31/2012] [Accepted: 08/02/2012] [Indexed: 12/12/2022]
|
18
|
Sasmal S, Balaji G, Kanna Reddy HR, Balasubrahmanyam D, Srinivas G, Kyasa SK, Sasmal PK, Khanna I, Talwar R, Suresh J, Jadhav VP, Muzeeb S, Shashikumar D, Harinder Reddy K, Sebastian VJ, Frimurer TM, Rist Ø, Elster L, Högberg T. Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists. Bioorg Med Chem Lett 2012; 22:3157-62. [PMID: 22487182 DOI: 10.1016/j.bmcl.2012.03.050] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2012] [Revised: 03/11/2012] [Accepted: 03/13/2012] [Indexed: 11/24/2022]
Abstract
Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1 homology models derived from the X-ray structure of the β2-adrenergic receptor, including extracellular loops, were developed and used to guide the design.
Collapse
Affiliation(s)
- Sanjita Sasmal
- Discovery Research, Dr. Reddy's Laboratories Ltd, Bollaram Road, Miyapur, Hyderabad 500049, India.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Sasmal S, Balasubrahmanyam D, Kanna Reddy HR, Balaji G, Srinivas G, Cheera S, Abbineni C, Sasmal PK, Khanna I, Sebastian V, Jadhav VP, Singh MP, Talwar R, Suresh J, Shashikumar D, Harinder Reddy K, Sihorkar V, Frimurer TM, Rist Ø, Elster L, Högberg T. Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2. Bioorg Med Chem Lett 2012; 22:3163-7. [DOI: 10.1016/j.bmcl.2012.03.049] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2012] [Revised: 03/11/2012] [Accepted: 03/13/2012] [Indexed: 10/28/2022]
|
20
|
|
21
|
Kamata M, Yamashita T, Imaeda T, Tanaka T, Terauchi J, Miyamoto M, Ora T, Tawada M, Endo S, Takekawa S, Asami A, Suzuki N, Nagisa Y, Nakano Y, Watanabe K, Ogino H, Kato K, Kato K, Ishihara Y. Discovery, synthesis, and structure-activity relationship of 6-aminomethyl-7,8-dihydronaphthalenes as human melanin-concentrating hormone receptor 1 antagonists. Bioorg Med Chem 2011; 19:5539-52. [PMID: 21856163 DOI: 10.1016/j.bmc.2011.07.038] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Revised: 07/19/2011] [Accepted: 07/20/2011] [Indexed: 10/17/2022]
Abstract
Human melanin-concentrating hormone receptor 1 (hMCHR1) antagonists are promising targets for obesity treatment. We identified the tetrahydronaphthalene derivative 1a with modest binding affinity for hMCHR1 by screening an in-house G protein-coupled receptor (GPCR) ligand library. We synthesized a series of 6-aminomethyl-5,6,7,8-tetrahydronaphthalenes and evaluated their activity as hMCHR1 antagonists. Modification of the biphenylcarbonylamino group revealed that the biphenyl moiety played a crucial role in the interaction of the antagonist with the receptor. The stereoselective effect of the chiral center on binding affinity generated the novel 6-aminomethyl-7,8-dihydronaphthalene scaffold without a chiral center. Optimization of the amino group led to the identification of a potent antagonist 2s (4'-fluoro-N-[6-(1-pyrrolidinylmethyl)-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide), which significantly inhibited the nocturnal food intake in rats after oral administration. Pharmacokinetic analysis confirmed that 2s had good oral bioavailability and brain penetrance. This antagonist appears to be a viable lead compound that can be used to develop a promising therapy for obesity.
Collapse
Affiliation(s)
- Makoto Kamata
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85 Jusohonmachi, 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Helal MA, Chittiboyina AG, Avery MA. New insights into the binding mode of melanin concentrating hormone receptor-1 antagonists: homology modeling and explicit membrane molecular dynamics simulation study. J Chem Inf Model 2011; 51:635-46. [PMID: 21370821 DOI: 10.1021/ci100355c] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Melanin concentrating hormone (MCH) is a cyclic 19-amino-acid peptide expressed mainly in the hypothalamus. It is involved in the control of feeding behavior, energy homeostasis, and body weight. Administration of MCH-R1 antagonists has been proved to reduce food intake and cause weight loss in animal models. In the present study, a homology model of the human MCH-R1 was constructed using the crystal structure of bovine rhodopsin (PDB: 1u19) as a template. Based on the observation that MCH-R1 can bind ligands of high chemical diversity, the initial model was subjected to an extensive ligand-supported refinement using antagonists of different chemotypes. The refinement process involved stepwise energy minimizations and molecular dynamics simulations. The refined model was inserted into a pre-equilibrated DPPC/TIP3P membrane system and then simulated for 20 ns in complex with structurally diverse antagonists. This protocol was able to explain the SAR of MCH-R1 antagonists with diverse chemical structures. Moreover, it reveals new insights into the critical recognition sites within the receptor. This work represents the first detailed study of molecular dynamics of MCH-R1 inserted into a membrane-aqueous environment.
Collapse
Affiliation(s)
- Mohamed A Helal
- Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, Mississippi 38677, United States
| | | | | |
Collapse
|
23
|
Cirauqui N, Schrey AK, Galiano S, Ceras J, Pérez-Silanes S, Aldana I, Monge A, Kühne R. Building a MCHR1 homology model provides insight into the receptor–antagonist contacts that are important for the development of new anti-obesity agents. Bioorg Med Chem 2010; 18:7365-79. [DOI: 10.1016/j.bmc.2010.09.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2010] [Revised: 09/02/2010] [Accepted: 09/07/2010] [Indexed: 12/29/2022]
|
24
|
Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists. Bioorg Med Chem Lett 2010; 20:5443-8. [DOI: 10.1016/j.bmcl.2010.07.086] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2010] [Revised: 07/20/2010] [Accepted: 07/22/2010] [Indexed: 11/19/2022]
|
25
|
Li J, Li S, Lei B, Liu H, Yao X, Liu M, Gramatica P. A new strategy to improve the predictive ability of the local lazy regression and its application to the QSAR study of melanin-concentrating hormone receptor 1 antagonists. J Comput Chem 2010; 31:973-85. [PMID: 19670228 DOI: 10.1002/jcc.21383] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
In the quantitative structure-activity relationship (QSAR) study, local lazy regression (LLR) can predict the activity of a query molecule by using the information of its local neighborhood without need to produce QSAR models a priori. When a prediction is required for a query compound, a set of local models including different number of nearest neighbors are identified. The leave-one-out cross-validation (LOO-CV) procedure is usually used to assess the prediction ability of each model, and the model giving the lowest LOO-CV error or highest LOO-CV correlation coefficient is chosen as the best model. However, it has been proved that the good statistical value from LOO cross-validation appears to be the necessary, but not the sufficient condition for the model to have a high predictive power. In this work, a new strategy is proposed to improve the predictive ability of LLR models and to access the accuracy of a query prediction. The bandwidth of k neighbor value for LLR is optimized by considering the predictive ability of local models using an external validation set. This approach was applied to the QSAR study of a series of thienopyrimidinone antagonists of melanin-concentrating hormone receptor 1. The obtained results from the new strategy shows evident improvement compared with the commonly used LOO-CV LLR methods and the traditional global linear model.
Collapse
Affiliation(s)
- Jiazhong Li
- State Key Laboratory of Applied Organic Chemistry, Department of Chemistry, Lanzhou University, Lanzhou 730000, China
| | | | | | | | | | | | | |
Collapse
|
26
|
Lee JY, Lee H, Lim JY, Yoo SE, Kang NS. Ionic interactions for substituted MCH1R inhibitors studied by pKa values. Bioorg Med Chem Lett 2009; 19:4376-9. [DOI: 10.1016/j.bmcl.2009.05.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2009] [Revised: 05/12/2009] [Accepted: 05/20/2009] [Indexed: 10/20/2022]
|
27
|
Moriya M, Kishino H, Sakuraba S, Sakamoto T, Suga T, Takahashi H, Suzuki T, Ito M, Ito J, Moriya R, Takenaga N, Iwaasa H, Ishihara A, Kanatani A, Fukami T. Identification of 2-aminobenzimidazoles as potent melanin-concentrating hormone 1-receptor (MCH1R) antagonists. Bioorg Med Chem Lett 2009; 19:3568-72. [DOI: 10.1016/j.bmcl.2009.04.147] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2009] [Revised: 04/27/2009] [Accepted: 04/29/2009] [Indexed: 11/30/2022]
|
28
|
V. Tverdokhlebov A, A. Chalyk B, T. Iminov R, A. Tolmachev A. Preparation of 5-Amino-1,2-dihydro-4-(1-methyl-4-piperidinyl)pyrrol-3-ones. HETEROCYCLES 2009. [DOI: 10.3987/com-09-11701] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
29
|
Lee NG, Yoo SE, Kang NS. The structure-based 3D-QSAR study of MCH1 receptor antagonists. MOLECULAR SIMULATION 2008. [DOI: 10.1080/08927020802129941] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Cavasotto CN, Orry AJW, Murgolo NJ, Czarniecki MF, Kocsi SA, Hawes BE, O'Neill KA, Hine H, Burton MS, Voigt JH, Abagyan RA, Bayne ML, Monsma FJ. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem 2008; 51:581-8. [PMID: 18198821 DOI: 10.1021/jm070759m] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Melanin-concentrating hormone receptor 1 (MCH-R1) is a G-protein-coupled receptor (GPCR) and a target for the development of therapeutics for obesity. The structure-based development of MCH-R1 and other GPCR antagonists is hampered by the lack of an available experimentally determined atomic structure. A ligand-steered homology modeling approach has been developed (where information about existing ligands is used explicitly to shape and optimize the binding site) followed by docking-based virtual screening. Top scoring compounds identified virtually were tested experimentally in an MCH-R1 competitive binding assay, and six novel chemotypes as low micromolar affinity antagonist "hits" were identified. This success rate is more than a 10-fold improvement over random high-throughput screening, which supports our ligand-steered method. Clearly, the ligand-steered homology modeling method reduces the uncertainty of structure modeling for difficult targets like GPCRs.
Collapse
|
31
|
Andersen D, Storz T, Liu P, Wang X, Li L, Fan P, Chen X, Allgeier A, Burgos A, Tedrow J, Baum J, Chen Y, Crockett R, Huang L, Syed R, Larsen RD, Martinelli M. Stereoselective Synthesis of a MCHr1 Antagonist. J Org Chem 2007; 72:9648-55. [DOI: 10.1021/jo701894v] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Denise Andersen
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Thomas Storz
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Pingli Liu
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Xin Wang
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Leping Li
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Pingchen Fan
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Xiaoqi Chen
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Alan Allgeier
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Alain Burgos
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Jason Tedrow
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Jean Baum
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Ying Chen
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Rich Crockett
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Liang Huang
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Rashid Syed
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Robert D. Larsen
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Mike Martinelli
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| |
Collapse
|
32
|
Méndez-Andino JL, Wos JA. MCH-R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov Today 2007; 12:972-9. [DOI: 10.1016/j.drudis.2007.08.010] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2007] [Revised: 08/08/2007] [Accepted: 08/21/2007] [Indexed: 10/22/2022]
|
33
|
Rokosz LL. Discovery and development of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Expert Opin Drug Discov 2007; 2:1301-27. [DOI: 10.1517/17460441.2.10.1301] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
34
|
Blakeney JS, Reid RC, Le GT, Fairlie DP. Nonpeptidic Ligands for Peptide-Activated G Protein-Coupled Receptors. Chem Rev 2007; 107:2960-3041. [PMID: 17622179 DOI: 10.1021/cr050984g] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jade S Blakeney
- Centre for Drug Design and Development, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | | |
Collapse
|
35
|
Luthin DR. Anti-obesity effects of small molecule melanin-concentrating hormone receptor 1 (MCHR1) antagonists. Life Sci 2007; 81:423-40. [PMID: 17655875 DOI: 10.1016/j.lfs.2007.05.029] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2007] [Revised: 05/09/2007] [Accepted: 05/18/2007] [Indexed: 10/23/2022]
Abstract
Over the past ten years, tremendous advances in our understanding of the role of the hypothalamic neurohormone, melanin-concentrating hormone (MCH), and its involvement in the regulation of food intake and body weight have been achieved. The MCHR1 receptor has been actively targeted as a much-needed, novel treatment for obesity, a disease of epidemic proportion in the United States. Numerous companies have joined the competition to be the first to produce a small molecule antagonist targeting MCHR1 receptors in the race for therapeutics for this disease. This review details the rising need for new treatments for obesity; the rationale and target validation of MCHR1 receptor antagonists as potential treatments for this disease; and the current status of the numerous small molecule MCHR1 antagonists in development by different companies. MCHR1 antagonists might find an additional usage in the treatment of anxiety and depression disorders. The rationale and current status of this effort by several companies is also reviewed.
Collapse
Affiliation(s)
- David R Luthin
- Samford University, McWhorter School of Pharmacy, 800 Lakeshore Drive, Birmingham, AL 35229, USA.
| |
Collapse
|
36
|
Giordanetto F, Karlsson O, Lindberg J, Larsson LO, Linusson A, Evertsson E, Morgan DGA, Inghardt T. Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists. Bioorg Med Chem Lett 2007; 17:4232-41. [PMID: 17532215 DOI: 10.1016/j.bmcl.2007.05.034] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2007] [Revised: 05/06/2007] [Accepted: 05/11/2007] [Indexed: 10/23/2022]
Abstract
We herein report the optimization of cyclopentane- and cyclohexane-1,3-diamine derivatives as novel and potent MCH-R1 antagonists. Structural modifications of the 2-amino-quinoline and thiophene moieties found in the initial lead compound served to improve its metabolic stability profile and MCH-R1 affinity, and revealed unprecedented SAR when compared to other 2-amino-quinoline-containing MCH-R1 antagonists.
Collapse
Affiliation(s)
- Fabrizio Giordanetto
- Lead Generation, Computational Chemistry, AstraZeneca R&D Mölndal, SE-431 83 Mölndal, Sweden.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists. Bioorg Med Chem Lett 2007; 17:3754-9. [PMID: 17448659 DOI: 10.1016/j.bmcl.2007.04.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2007] [Revised: 03/31/2007] [Accepted: 04/05/2007] [Indexed: 11/16/2022]
Abstract
We report here new chemical series acting as antagonists of melanin-concentrating hormone receptor 1 (MCHR-1). Synthesis and structure-activity relationships are described leading to the identification of compounds with optimized in vitro pharmacological and in vitro ADME profiles. In vivo activity has been demonstrated in animal models of food intake and depression.
Collapse
|
38
|
Arienzo R, Cramp S, Dyke HJ, Lockey PM, Norman D, Roach AG, Smith P, Wong M, Wren SP. Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett 2007; 17:1403-7. [PMID: 17178222 DOI: 10.1016/j.bmcl.2006.11.092] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2006] [Revised: 11/20/2006] [Accepted: 11/30/2006] [Indexed: 10/23/2022]
Abstract
We have modified the previously reported 2-aminoquinoline 1 to provide two novel series of MCH-1R antagonists. Representative compounds from the quinazoline and benzimidazole series have been shown to be potent and selective, with promising in vitro eADME profiles.
Collapse
Affiliation(s)
- Rosa Arienzo
- Argenta Discovery Limited, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Méndez-Andino J, Colson AO, Denton D, Mitchell MC, Cross-Doersen D, Hu XE. MCH-R1 antagonists based on an arginine scaffold: SAR studies on the amino-terminus. Bioorg Med Chem Lett 2007; 17:832-5. [PMID: 17107794 DOI: 10.1016/j.bmcl.2006.10.056] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2006] [Revised: 10/13/2006] [Accepted: 10/23/2006] [Indexed: 10/24/2022]
Abstract
We have identified a novel series of potent MCH-R1 antagonists based on l-arginine. As predicted by computational methods, there was an activity dependence on the pi-electronic character of the aromatic systems corresponding to the amino-terminus of these molecules. These results have enhanced our understanding of the MCH-R1 receptor and the potential for a predictive homology model.
Collapse
Affiliation(s)
- José Méndez-Andino
- Procter & Gamble Pharmaceuticals, 8700 Mason-Montgomery Road, Mason, OH 45039, USA.
| | | | | | | | | | | |
Collapse
|
40
|
Meyers KM, Méndez-Andino J, Colson AO, Hu XE, Wos JA, Mitchell MC, Hodge K, Howard J, Paris JL, Dowty ME, Obringer CM, Reizes O. Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonists. Bioorg Med Chem Lett 2007; 17:657-61. [PMID: 17174091 DOI: 10.1016/j.bmcl.2006.10.096] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2006] [Revised: 10/30/2006] [Accepted: 10/31/2006] [Indexed: 10/23/2022]
Abstract
The synthesis and biological testing of novel classes of potent melanin-concentrating hormone (MCH-R1) antagonists based on pyrazolopiperazinone and pyrrolopiperazinone scaffolds are described.
Collapse
Affiliation(s)
- Kenneth M Meyers
- Procter and Gamble Pharmaceuticals, 8700 Mason-Montgomery Road, Mason, OH 45039, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Goodnow RA, Gillespie P. 1Hit and Lead Identification: Efficient Practices for Drug Discovery. PROGRESS IN MEDICINAL CHEMISTRY 2007; 45:1-61. [PMID: 17280901 DOI: 10.1016/s0079-6468(06)45501-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Robert A Goodnow
- Discovery Chemistry, Roche Research Center, Nutley, NJ 07110-1199, USA
| | | |
Collapse
|
42
|
Méndez-Andino JL, Colson AO, Meyers KM, Mitchell MC, Hodge K, Howard JM, Kim N, Ackley DC, Holbert JK, Mittelstadt SW, Dowty ME, Obringer CM, Suchanek P, Reizes O, Hu XE, Wos JA. The efficacy and cardiac evaluation of aminomethyl tetrahydronaphthalene ketopiperazines: a novel class of potent MCH-R1 antagonists. Bioorg Med Chem 2006; 15:2092-105. [PMID: 17236777 DOI: 10.1016/j.bmc.2006.12.028] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2006] [Revised: 11/18/2006] [Accepted: 12/15/2006] [Indexed: 11/28/2022]
Abstract
The design, synthesis, and biological studies of a novel class of MCH-R1 antagonists based on an aminotetrahydronaphthalene ketopiperazine scaffold is described. Compounds within this class promoted significant body weight reduction in mouse diet induced obesity studies. The potential for hERG blockage activity and QT interval studies in anesthetized dogs are discussed.
Collapse
Affiliation(s)
- José L Méndez-Andino
- Procter & Gamble Pharmaceuticals, 8700 Mason-Montgomery Road, Mason, OH 45039, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Jiang J, Hoang M, Young JR, Chaung D, Eid R, Turner C, Lin P, Tong X, Wang J, Tan C, Feighner S, Palyha O, Hreniuk DL, Pan J, Sailer AW, MacNeil DJ, Howard A, Shearman L, Stribling S, Camacho R, Strack A, Van der Ploeg LHT, Goulet MT, DeVita RJ. 2-Aminoquinoline melanin-concentrating hormone (MCH)1R antagonists. Bioorg Med Chem Lett 2006; 16:5270-4. [PMID: 16919456 DOI: 10.1016/j.bmcl.2006.08.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2006] [Revised: 07/31/2006] [Accepted: 08/01/2006] [Indexed: 11/27/2022]
Abstract
A series of 2-aminoquinoline compounds was prepared and evaluated in MCH1R binding and functional antagonist assays. Small dialkyl, methylalkyl, methylcycloalkyl, and cyclic amines were tolerated at the quinoline 2-position. The in vivo efficacy of compound 12 was explored and compared to that of a related inactive analog to determine their effects on food intake and body weight in rodents.
Collapse
Affiliation(s)
- Jinlong Jiang
- Department of Medicinal Chemistry, PO Box 2000, Rahway, NJ 07065-0900, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Jiang J, Lin P, Hoang M, Chang L, Tan C, Feighner S, Palyha OC, Hreniuk DL, Pan J, Sailer AW, Morin NR, MacNeil DJ, Howard AD, Van der Ploeg LHT, Goulet MT, DeVita RJ. 4-Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists. Bioorg Med Chem Lett 2006; 16:5275-9. [PMID: 16919453 DOI: 10.1016/j.bmcl.2006.08.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2006] [Revised: 07/31/2006] [Accepted: 08/01/2006] [Indexed: 11/18/2022]
Abstract
Structure-activity relationships of a 4-aminoquinoline MCH1R antagonist lead series were explored by synthesis of analogs with modifications at the 2-, 4-, and 6-positions of the original HTS hit. Improvements to the original screening lead included lipophilic groups at the 2-position and biphenyl, cyclohexyl phenyl, and hydrocinnamyl carboxamides at the 6-position. Modifications of the 4-amino group were not well tolerated.
Collapse
Affiliation(s)
- Jinlong Jiang
- Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065-0900, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Hudson S, Kiankarimi M, Rowbottom MW, Vickers TD, Wu D, Pontillo J, Ching B, Dwight W, Goodfellow VS, Schwarz D, Heise CE, Madan A, Wen J, Ban W, Wang H, Wade WS. Synthesis and structure–activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2. Bioorg Med Chem Lett 2006; 16:4922-30. [PMID: 16824755 DOI: 10.1016/j.bmcl.2006.06.049] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2006] [Revised: 06/13/2006] [Accepted: 06/14/2006] [Indexed: 11/20/2022]
Abstract
The design, synthesis, and SAR of a series of retro bis-aminopyrrolidine ureas are described. Compounds from this series exhibited considerable binding affinity (Ki = 1 nM) and functional activity at MCH-R1, acceptable CYP2D6 inhibition, and good rat brain exposure.
Collapse
Affiliation(s)
- Sarah Hudson
- Department of Medicinal Chemistry, Neurocrine Biosciences Inc., 12790 El Camino Real, San Diego, CA 92130, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Rowbottom MW, Vickers TD, Dyck B, Grey J, Tamiya J, Zhang M, Kiankarimi M, Wu D, Dwight W, Wade WS, Schwarz D, Heise CE, Madan A, Fisher A, Petroski R, Goodfellow VS. Synthesis and structure–activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 1. Bioorg Med Chem Lett 2006; 16:4450-7. [PMID: 16814542 DOI: 10.1016/j.bmcl.2006.06.045] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2006] [Revised: 06/12/2006] [Accepted: 06/12/2006] [Indexed: 10/24/2022]
Abstract
The design, synthesis, and SAR of a series of retro bis-aminopyrrolidine ureas are described. Compounds from this series exhibited potent binding affinity and functional activity at MCH-R1, and good oral bioavailability in rat.
Collapse
Affiliation(s)
- Martin W Rowbottom
- Department of Medicinal Chemistry, Neurocrine Biosciences Inc., San Diego, CA 92130, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Witty DR, Bateson JH, Hervieu GJ, Jeffrey P, Johnson CN, Muir AI, O'Hanlon PJ, Stemp G, Stevens AJ, Thewlis KM, Wilson S, Winborn KY. SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): Discovery of antagonist SB-568849. Bioorg Med Chem Lett 2006; 16:4865-71. [PMID: 16839761 DOI: 10.1016/j.bmcl.2006.06.056] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2006] [Revised: 06/14/2006] [Accepted: 06/15/2006] [Indexed: 11/29/2022]
Abstract
We report here the discovery of a class of MCH R1 ligands based on a biphenyl carboxamide template. A docked-in model is presented indicating key interactions in the putative binding site of the receptor. Parallel high throughput synthetic techniques were utilised to allow rapid exploration of the structure-activity relationship around this template, leading to compound SB-568849 which possessed good receptor affinity and selectivity. This compound proved to be an antagonist with stability in vivo, an acceptable brain-blood ratio and oral bioavailability.
Collapse
Affiliation(s)
- David R Witty
- GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Ulven T, Little PB, Receveur JM, Frimurer TM, Rist O, Nørregaard PK, Högberg T. 6-Acylamino-2-amino-4-methylquinolines as potent melanin-concentrating hormone 1 receptor antagonists: Structure–activity exploration of eastern and western parts. Bioorg Med Chem Lett 2006; 16:1070-5. [PMID: 16289819 DOI: 10.1016/j.bmcl.2005.10.066] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2005] [Revised: 10/19/2005] [Accepted: 10/20/2005] [Indexed: 11/26/2022]
Abstract
SAR explorations of the eastern and western parts of recently disclosed 2-aminoquinoline MCH1R-antagonists are reported. Eastern part investigations confirmed a high degree of structural freedom, and a number of additional single digit nanomolar antagonists were identified. Investigations of the western part also confirmed the initial SAR analysis, requiring a para-substituted phenyl ring spaced from the 6-amide by two connecting atoms. The exploration led to the discovery of a novel sub-series with a 4-biphenylcarboxamide western part, also exhibiting single digit nanomolar affinity.
Collapse
Affiliation(s)
- Trond Ulven
- 7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hørsholm, Denmark
| | | | | | | | | | | | | |
Collapse
|